NASDAQ:OGI - Nasdaq - CA68617J1003 - Common Stock - Currency: USD
Organigram's Q2 sales surged 74% to $45.7 million, driven by Motif and global growth, with net income swinging to CA$42.5 million from a loss a year ago.
OrganiGram (OGI) delivered earnings and revenue surprises of -333.33% and 29.59%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: TLSI
Mentions: OGI.CA
InfuSystems Holdings (INFU) delivered earnings and revenue surprises of 66.67% and 4.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: INFU
Mentions: OGI.CA
Mentions: OGI.CA
Mentions: OGI.CA
Bio-Rad (BIO) delivered earnings and revenue surprises of 46.82% and 0.05%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BIO
Mentions: OGI.CA
Mentions: OGI.CA
Mentions: OGI.CA
Mentions: OGI.CA
(Reuters) -Levi Strauss maintained on Monday its annual forecast for sales and profit, excluding the impact of tariffs, and posted quarterly profit ahead of Wall Street targets, sending its shares up more than 7% in after hours trade. Sweeping tariffs by President Donald Trump have sparked concerns over a global downturn and sharp price hikes for items such as clothing and footwear. "While we recognize that we are operating in an uncertain environment, our global footprint, strong margin structure, and agile supply chain position us to navigate the balance of the year and beyond," President and Chief Executive Michelle Gass said in a statement on Monday.
Mentions: OGI.CA
Mentions: OGI.CA
Mentions: OGI.CA
Mentions: OGI.CA
Mentions: OGI.CA
OGI earnings call for the period ending December 31, 2024.
Mentions: OGI.CA
Mentions: OGI.CA